MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88
Open Access
- 1 July 2017
- journal article
- Published by Elsevier in Mucosal Immunology
- Vol. 10 (4) , 924-935
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Sensing of cell death by myeloid C-type lectin receptorsCurrent Opinion in Immunology, 2013
- Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibioticsInternational Urogynecology Journal, 2012
- Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1βNature, 2012
- C-type lectin receptor-induced NF-κB activation in innate immune and inflammatory responsesCellular & Molecular Immunology, 2012
- Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification systemInternational Journal of Antimicrobial Agents, 2011
- The many routes of dendritic cells to ensure immune regulationJournal of Allergy and Clinical Immunology, 2011
- Syk-coupled C-type lectins in immunityTrends in Immunology, 2011
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Dendritic cells and macrophages in the genitourinary tractMucosal Immunology, 2008
- Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cellsInternational Immunology, 2004